New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
16:07 EDTCTICCell Therapeutics sees FY13 loss from operations $60M-$65M
For 2013, loss from operations is expected to be approximately $60M-$65M, excluding non-cash stock-based compensation expense. The projected decrease in 2013 loss from operations, compared to 2012, primarily relates to expected changes in contribution margin from PIXUVRI commercial operations, as it intends to operate the commercial business with a net positive contribution; SG&A expenses, including sales and marketing expenses to drive sales of PIXUVRI; and R&D expenses.
News For CTIC From The Last 14 Days
Check below for free stories on CTIC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 7, 2014
09:08 EDTCTICOn The Fly: Pre-market Movers
Subscribe for More Information
05:44 EDTCTICCTI BioPharma announces Pacritinib granted fast track designation by FDA
CTI BioPharma announced that pacritinib has been granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. Pacritinib is an oral tyrosine kinase inhibitor with dual activity against JAK2 and FLT3. The drug candidate is currently being evaluated in two Phase 3 clinical trials, known as the PERSIST program, for patients with myelofibrosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use